RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All EMA (EU) updates
EMA (EU)
GUIDANCE FINAL
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products - Revision 1
Published: 11/13/2026Detected: 11/13/2026

Summary preview

Outlines EMA CVMP data expectations for introducing a heat treatment step to inactivate endogenous retroviruses (e.g., RD114) in the production of live viral immunological veterinary medicinal products, including how to…

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
immunology
infectious_disease
rare_diseases
#EMA
#CVMP
#IWP
#endogenous retrovirus
#RD114

Official Source Document
Source Verified

Access the original document directly from EMA.

View Official Document

More from EMA (EU)

  • Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
  • Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
  • EMA annual call with General Practitioner Organisations' representatives11/20/2026
  • Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
  • Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026

Get EMA (EU) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.